top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Recent Biopharma Funding Activity - April 8th

Check out the following recent activity in the biopharma funding space. Take a closer look at 43 notable updates for this week:


Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)


– Private Funding –


Surrozen 

💸 Entered into a $192.5M private placement to fund the SZN-043 clinical development program.


Obsidian Therapeutics

💸 Raised $160.5M Series C financing led Wellington Management and will go towards enrolling more patients for its OBX-115 drug trial for NSCLC.


ImmPACT Bio USA Inc.

💸 $141.7M offering w/ $139.8M already sold. 


Alterome Therapeutics 

💸 Raised $132M in Series B financing led by Goldman Sachs Alternatives to advance the development of the AKT1 E17K & KRAS selective inhibitor candidates.  


Diagonal Therapeutics 

💸 Launched w/ $128M in financing to pioneer a new approach to discovering and developing agonist antibodies.


ImmunoGenesis, Inc.

💸 $66.5M offering w/ $44.4M already sold. 


Neurosterix 

💸 Launched w/ $63M funding to advance allosteric modulator therapeutics (e.g., M4 PAM) for neurological disorders. 


Biolinq 

💸 Raised $58M in funding led by Alpha Wave Ventures to support the completion pivotal trial this year, proprietary intradermal glucose sensor evaluation, and subsequent FDA submission. 


Selux Diagnostics 

💸 Raised an additional $48M in funding to launch their next phase of commercialization of the Selux Next Generation Phenotyping (NGP) system within the US.


Protara Therapeutics 

💸 Entered into an oversubscribed $45M private placement financing to fund the company into 2026.


EnteroBiotix 

💸 Completed £27M ($34M) funding round supported by various investors to advance EBX-102-02 through a Ph2 trial treating IBS and also to other drug pipelines. 


Melt Pharmaceuticals 

💸 Closed $24M Series B funding from various investors to further the development of MELT-300.


Biofidelity 

💸 Raised $24M financing to accelerate commercialization of ASPYRE®-Lung novel test for NSCLC in the US. 


Miach Orthopaedics 

💸 Raised $20M in Series B extension funding to support commercial expansion and clinical activities for the BEAR implant for anterior cruciate ligament (ACL) tears. 


iBio, Inc.

💸 $15M equity financing


Delphinus Medical Technologies, Inc.

💸 $15M debt financing w/ $5.2M already sold.


Delova Biotech

💸 Completed >100M CNY ($14M) in Series B+ financing led by several investors


UniXell Biotechnology

💸 Completed >100M CNY ($14M) in Series A financing led by Tasly Capital to accelerate the clinical research pipeline and support the industrialization of innovative cell therapy drugs.


Conformation-X Therapeutics 

💸 Secured $13.5M in funding to advance its immune-oncology pipeline. 


AI Proteins, Inc.

💸 $10M debt financing w/ $4.9M already sold.


Carmell Corp.

💸 Announces $3M private placement.


Mach5 Therapeutics, Inc.

💸 $2.9M offering w/ $2.6M already sold. 


Mercury Bio, Inc.

💸 $2M offering w/ $149.9K already sold. 


Juniper Biomedical 

💸 Secured $2M Series Seed funding led by Auroral Holdings and $1M through the NIH SPARC Neuromod prize to accelerate development in the pelvic health disorders space.


Precision Epigenomics Inc

💸 $1.7M offering w/ $1.1M already sold. 


Anchor Balloon, Inc.

💸 $1.5M debt financing. 


BetterLife 

💸 Closed $1.168M convertible debentures to further advance IND-enabling studies of its non-hallucinogenic LSD-based candidate, BETR-001. 


Medibiofarma

💸 Closed €1M ($1M) financing round to further the clinical phase of MBF-118, MBF-015, and MBF-362. 


Ironic Biotech 

💸 Raised €1M ($1M) led by Nordic Foodtech VC to develop interventions for both iron deficiency and anemia. 


Cessation Therapeutics

💸 $1M offering. 


Addiction Cure Therapeutic Sciences Inc

💸 $1M offering. 


Bio-Path Holdings, Inc.

💸 $317K warranted option.


Gemina Laboratories Ltd.

💸 $302K debt financing.


Sirona Biochem 

💸 Closed CAD 132K ($97K) of private placement to be used for general working capital. 


Swan NeuroTech, Inc.

💸 $95K debt financing




– Post-IPO/Public Funding –


Rhythm Pharmaceuticals 

💸 Sold $150M in Series A convertible preferred stock in a financing led by Perceptive Advisors, LLC. The financing extends its cash runway into 2026, enabling a topline data readout from its Ph3 trial in hypothalamic obesity in H1 2025.


Gritstone bio 

🏦 $32M public offering. 


Sutro Biopharma 

🏦 $7M underwritten offering.


BioLineRx 

🏦 $6M registered direct offering.


Biora Therapeutics 

🏦 $6M registered direct offering.


Matinas BioPharma 

🏦 $10M registered direct offering.


SINTX Technologies 

🏦 $1.5M public offering.


RedHill Biopharma 

🏦 $1.25M registered direct offering.



FIG. 1. Recent Biotech Funding Activity



FIG. 2. Public Funding per Disease Category for Apr 1-5 Public Company Funding Events



---


Article History:

RF, DV (04/09/24)

Kommentare


bottom of page